Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Reckitt Benckiser Group plc
  6. News
  7. Summary
    RB.   GB00B24CGK77

RECKITT BENCKISER GROUP PLC

(RB.)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Reckitt Benckiser sees more sales growth, names chairman for pharma unit

02/12/2014 | 04:36am EDT
Products produced by Reckitt Benckiser; Harpic, Vanish, Dettol and Finish, are seen in London

LONDON (Reuters) - Consumer goods group Reckitt Benckiser reported a rise in sales and forecast further growth this year, despite challenges in emerging markets, and named a new chairman for its declining pharmaceuticals business to help with a strategic review.

The company did not say what option it was leaning towards for the business, which centres on the opioid-dependence drug Suboxone, but some analysts took the appointment of drugs industry veteran Howard Pien chairman as a sign it might be preparing for a sale.

"The appointment of a chairman of this business might be taken as implying a spin-out is a serious possibility," analysts at Credit Suisse said in a research note.

CS values the pharmaceuticals business at about 1.5 billion pounds, or just over 200 pence a share.

Shares in Reckitt were up 0.7 percent at 4865 pence by 0856 GMT on Wednesday, valuing the entire group at 35 billion pounds.

Reckitt, whose wide range of household, health and personal brands include Lysol disinfectant and Durex condoms earlier reported that fourth-quarter like-for-like sales excluding its drug business rose 4 percent. The consensus forecast from analysts in a company-supplied survey was for an increase of 4.2 percent.

Including the impact of acquisitions, quarterly revenue excluding Suboxone, rose 7 percent to 2.32 billion pounds. That exceeded company targets, due to swift integration and cost-savings.

"Market conditions are more challenging now than at the beginning of last year, particularly in some emerging markets," Chief Executive Rakesh Kapoor said in a statement. Still, he said he was confident the company's pipeline of new products and investments would deliver growth this year.

Reporting earnings down 4 percent at 238.5 pence a share but up 2 percent at 269.8 pence before exceptionals, the company raised its total dividend by 2 percent to 137 pence a share, including the final payout of 77 pence.

For 2014, Reckitt forecast revenue growth of another 4 to 5 percent, with flat to moderate operating margin expansion, excluding Suboxone.

Reckitt said in October it was considering all options for the business, which is declining due to competition from cheaper generic versions. It said on Wednesday that the review was continuing and that it would update investors over the course of the year.

Regarding acquisitions, Kapoor said Reckitt would continue to be active in consumer healthcare, but declined to comment on a recent Reuters report that companies like Reckitt could be interested in buying U.S. drugmaker Merck & Co's $8-10 billion consumer healthcare business.

(Editing by Greg Mahlich)

By Martinne Geller


ę Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. -0.89% 75.74 Delayed Quote.-6.59%
RECKITT BENCKISER GROUP PLC 0.77% 5663 Delayed Quote.-14.09%
RISE, INC. 0.00% 26 End-of-day quote.8.33%
All news about RECKITT BENCKISER GROUP PLC
05:26aRECKITT BENCKISER : Taking to the skies with new Eurowings partnership
PU
08/03Clorox forecasts drop in annual sales as pandemic boom fades, shares fall
RE
08/02WALL STREET STOCK EXCHANGE : US stocks continue to outperform their internationa..
08/02RECKITT BENCKISER : Bernstein Upgrades Reckitt Benckiser To Market-Perform From ..
MT
08/02RECKITT BENCKISER GROUP PLC : Bernstein drops its Sell rating
MD
08/02ANALYST RECOMMENDATIONS : ConvaTec, DiscoverIE, LKQ, Unite Group, WidomTree...
08/02TAKE FIVE : Jobs, crackdowns and a fork
RE
07/29RECKITT BENCKISER GROUP PLC : Jefferies reaffirms its Neutral rating
MD
07/29RECKITT BENCKISER : Jefferies Cuts Reckitt Benckiser PT, Maintains Hold Rating
MT
07/29RECKITT BENCKISER : Goldman Sachs Keeps Reckitt Benckiser At Neutral, Cuts PT
MT
More news
Financials
Sales 2021 13 147 M 18 281 M 18 281 M
Net income 2021 2 134 M 2 967 M 2 967 M
Net Debt 2021 8 384 M 11 658 M 11 658 M
P/E ratio 2021 18,8x
Yield 2021 3,11%
Capitalization 40 139 M 55 800 M 55 815 M
EV / Sales 2021 3,69x
EV / Sales 2022 3,64x
Nbr of Employees 43 500
Free-Float 96,7%
Chart RECKITT BENCKISER GROUP PLC
Duration : Period :
Reckitt Benckiser Group plc Technical Analysis Chart | RB. | GB00B24CGK77 | MarketScreener
Technical analysis trends RECKITT BENCKISER GROUP PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 5 620,00 GBX
Average target price 7 114,14 GBX
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Laxman Narasimhan Group Chief Executive Officer & Executive Director
Jeff Carr Chief Financial Officer & Executive Director
Christopher A. Sinclair Chairman
Aditya Sehgal Chief Operating Officer-Health
Nicandro Durante Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
RECKITT BENCKISER GROUP PLC-14.09%55 775
PROCTER & GAMBLE COMPANY3.46%349 755
UNILEVER PLC-5.38%149 888
THE ESTÉE LAUDER COMPANIES INC.23.05%118 737
HINDUSTAN UNILEVER LIMITED-0.69%75 533
COLGATE-PALMOLIVE COMPANY-6.98%66 992